A Summary of CBPartners’ Posters and Workshops from Virtual ISPOR 2020

This week CBPartners attended the heavily anticipated Virtual ISPOR 2020. A global conference that welcomes health professionals from around the world and this year hosted more than 1300 attendees from 54 countries. The event enables representatives from all areas of healthcare to come together to hear from experts and stakeholders covering the most critical and current issues faced in HEOR today.

CBPartners is proud to have had six research posters to present at the conference, along with one virtual workshop. Below we have detailed each poster and workshop, along with a link to the pdf, as well as contact information should you wish to discuss the topic or themes further.

The Evolving and Interesting Topics Presented by CBPartners at Virtual ISPOR 2020

  1. (PNS40) THE USE OF INTEGRATED DELIVER NETWORKS AS PIONEERS FOR MANUFACTURER HEOR PROGRAM / STUDY SUCCESS

LINK: bit.ly/2Z6Qqlg

CBP Summary: The research of this poster aimed to identify the impact of utilizing Integrated Delivery Networks (IDNs) and their in-house resources in fulfilling HEOR program requirements. Overall, findings suggest the replication of results to managed care organizations is a subsequent step, but IDNs offer a good first prospect for assessing HEOR program impact.

Contact: Andrew Gould, andrew.gould@cbpartners.com

 

  1. (PCN221) OCM TO OCF: IMPLICATIONS FOR TOTAL COST OF CARE

LINK: bit.ly/3dO1R5s

CBP Summary: A study to review the oncology care model (OCM) and map the limitations of the proposed features of the 2021 model, in order to establish whether the OCF is more likely to successfully reduce total cost of care specifically within the oncology landscape.

Contact: Monica Martin De Bustamante, monica.bustamante@cbpartners.com

 

 

  1. (PR099) EVALUATING THE HTA IMPACT OF REAL-WORLD EVIDENCE FROM FORMAL ORPHAN DRUG REGISTRIES

LINK: bit.ly/35ZKyM5

CBP Summary: A comparative assessment of the formal registry requirements in Germany and Brazil for orphan therapies with limited clinical evidence. The poster evaluates the future role of real-world evidence (RWE) in health technology assessments and provides findings that suggest RWE from formal registries is unlikely to have significant positive impact on future HTA decisions.

Contact: Monica Martin De Bustamante, monica.bustamante@cbpartners.com

 

  1. (PNS134) RE-SUBMISSIONS WITH RWE: CAN THEY HELP CHANGE YOUR BENEFIT RATING?

LINK: bit.ly/3dOmwq4

CBP Summary: Research aimed at understanding the role of RWE re-submissions to determine the type of evidence that can be used to help improve HTA outcomes when products are re-assessed by the HAS in France and the G-BA in Germany.

Contact: Monica Martin De Bustamante, monica.bustamante@cbpartners.com

 

 

  1. (PMU37) THE RESULTANT IMPACT OF HEOR DATA ON US PAYER FORMULARY COVERAGE

LINK: bit.ly/2T65pIn

CBP Summary: An analysis to identify instances where manufacturer HEOR data and/or pharmaeconomic models either influenced positive changes or had limited tangible impact on resultant US payer coverage decisions. With research concluding payers are more likely to perceive manufacturer-submitted data favorably and implement positive formulary changes when the HEOR data is generate via credible, independent 3rd part sources.

Contact: Andrew Gould, andrew.gould@cbpartners.com

 

  1. (PNS101) COLLABORATIVE APPROACHES TO ATTAIN HEALTHCARE SUSTAINABILTY IN LATIN AMERICA

LINK: https://bit.ly/2XcYy0J 

CBP Summary: Research aimed at identifying hurdles to achieving healthcare sustainability in Latin America (LA) while reviewing approaches taken by policy makers to control healthcare budgets and propose actionable solutions to attain sustainability that mutually benefit healthcare systems and industry. Overall, findings show that across LA, demand for health services outpaced supply, with countries in the region lacking the adequate clinical and technological resources and infrastructure to address the increased demand.

Contact: Miguel Martin De Bustamante, miguel.bustamante@cbpartners.com

 

  1. (W15) PRICING THE ‘PROMISE’ OF A CURE: HOW RWE MAY BECOME THE NEW LEVER FOR PAYER RE-NEGOTIATIONS

 
CBP Summary: With the goal to highlight the relevance and importance of RWE data collection for innovative treatments such as cell and gene therapies. This workshop addressed the key issues that relate to the collection and evaluation of RWE in the context of single or short-term treatments. The key challenges from the payer and manufacturer perspectives were also covered while outlining potential targeted mitigation strategies.

Contact: Max Hunt, maximilian.hunt@cbpartners.com

Until Next Time ISPOR

CBPartners is proud to attend and participate in ISPOR conferences and is very much looking forward to ISPOR EU later in the year. We would like to extend a special thank you to our workshop panellists Melanie WhittingtonJudith Glennie and Fabrizio Gianfrate who joined us to discuss key issues and considerations surrounding the collection and evaluation of real-world evidence in single or short-term treatments during the thought provoking session.

Additionally, a huge thank you to FIFARMA who collaborated on the Latin America focused poster which proposed short, medium, and long-term plans to ensure quality and effective health coverage in the region.

Authors